We’re proud to be part of such a tight-knit community. The more we can stay in touch, the closer we can work together. Click subscribe to receive news and updates about Amylyx.
Characterizing the CSF Biomarker Signature of Calpain-2 Activity in ALS and Its Application in the Phase 1 LUMINA Trial
Lead Author: Robert Bowser, PhD (Presenter)
Published: 36th International Symposium on ALS/MND (MNDA)
Date: December 6, 2025
A Phase 1, Multicenter, Randomized, Placebo-Controlled Multiple Ascending Dose Study to Evaluate the Safety and Tolerability of AMX0114 in Amyotrophic Lateral Sclerosis (LUMINA)
Lead Author: Sabrina Paganoni, MD, PhD (Presenter)
Published: 36th International Symposium on ALS/MND (MNDA)
Date: December 5, 2025
48-Week Results from the Phase 2, Open-Label Study Evaluating an Oral, Fixed-Dose Combination of Sodium Phenylbutyrate and Taurursodiol (PB&TURSO) in Wolfram Syndrome
Lead Author: Jamie Timmons, MD
Published: The Wolfram Syndrome UK and Snow Foundation Virtual Global Research and Trial Update
Date: November 15, 2025
LUMINA Study Update
Lead Author: Lauren Kett, MD, PhD and Sabrina Paganoni, MD, PhD (Co-Presenters)
Published: 2025 Annual NEALS Meeting
Date: October 8, 2025
Poster: Characterizing the CSF Biomarker Signature of Calpain-2 Activity in ALS and the Biomarker Impact of Calpain-2 Inhibition in a Preclinical Model of ALS
Lead Author: Robert Bowser, PhD (Presenter)
Published: 2025 Annual NEALS Meeting
Date: October 8, 2025
Presentation: Characterizing the CSF Biomarker Signature of Calpain-2 Activity in ALS and the Biomarker Impact of Calpain-2 Inhibition in a Preclinical Model of ALS
Lead Author: Robert Bowser, PhD (Presenter)
Published: 2025 Annual NEALS Meeting
Date: October 8, 2025
Update on the Phase 2b Portion of the ORION Trial in Progressive Supranuclear Palsy (PSP)
Lead Author: Anne-Marie Wills, MD (Presenter)
Published: International Congress of Parkinson’s Disease and Movement Disorders 2025
Date: October 7, 2025
Poster: Reduction in Rate of Hypoglycemic Events with Avexitide in Post-Bariatric Hypoglycemia: Results from the Phase 2 and 2B Studies
Lead Author: Marilyn Tan, MD, FACE (Presenter)
Published: Endocrine Society’s Annual Meeting (ENDO 2025)
Date: July 13, 2025
Presentation: Reduction in Rate of Hypoglycemic Events with Avexitide in Post-Bariatric Hypoglycemia: Results from the Phase 2 and 2B Studies
Lead Author: Marilyn Tan, MD, FACE (Presenter)
Published: Endocrine Society’s Annual Meeting (ENDO 2025)
Date: July 13, 2025
Population PK (PopPK) and Pharmacokinetic/Pharmacodynamic (PK/PD) Analysis of Avexitide in Individuals with Post-Bariatric Hypoglycemia
Lead Author: Kelly Fox, MD (Presenter)
Published: Endocrine Society’s Annual Meeting (ENDO 2025)
Date: July 12, 2025